摘要
目的： 初步评价ST段抬高型急性心肌梗死（STEMI）尿激酶溶栓治疗后急诊经皮冠状动脉介入治疗（PCI）过程中应用比伐芦定的安全性。方法： 回顾分析2012年10月-2013年8月于尿激酶溶栓后3-24 h内行急诊PCI治疗过程中应用了比伐芦定16例患者的资料（比伐芦定组），按1∶2匹配选取既往急诊PCI治疗过程中常规应用普通肝素的此类患者资料，按性别、年龄、病变血管相匹配纳入32例患者作为对照组（普通肝素组），分析术后30 d内的主要终点事件（包括全因死亡、再发心肌梗死）以及严重出血性并发症的发生情况。结果： 两组基线资料对比，差异无显著意义。30 d内普通肝素组1例发生主要终点事件及1例严重出血并发症，两组间主要终点事件和严重出血并发症发生率差异无统计学意义。结论： STEMI尿激酶溶栓治疗后行急诊PCI过程中应用比伐芦定相对安全。
AIM： To evaluate the safety of bivalirudin in percutaneous coronary intervention following urokinase thrombolytic therapy. METHODS： Medical records were analyzed in the 16 patients who were given bivalirudin during emergency PCI within 3 -24 h of thrombolytic therapy between October 2012 and August 2013 （bivalirudin group）. The same type of records were screened where unfractionated heparin （UFH） was used during emergency PCI at a ratio of 1：2 for the control group of 32 patients based on age- and sex-matching and target coronary artery （UFH group）. The main endpoint events including all-cause mortality and re-infarction and severe bleeding complications were compared between groups. RESULTS ： Comparison of baseline data between groups showed no significant difference. There was one occurrence of endpoint event and one severe bleeding event within 30 days in the occurrence of main endpoint event and severe bleeding complication significant. CONCLUSION： Bivalirudin in percutaneous coronary thrombolytic therapy is safe. in the UFH group. The difference between groups was not statistically intervention following urokinase
出处
《心脏杂志》
CAS
2015年第1期20-22,共3页
Chinese Heart Journal
基金
上海市静安区重点学科项目资助(JWXK201201)
